Skip to main content
. 2024 Jun 12;300(7):107463. doi: 10.1016/j.jbc.2024.107463

Figure 3.

Figure 3

USP36 downregulation diminishes the levels of several antiapoptotic proteins from the Bcl-2 and IAP families. A, HCT 116 cells were untreated (−) or transfected with control siRNA (Ctrl), siUSP36#1 (#1), and siUSP36#2 (#2) for 72 h. Proteins were extracted and immunoblotted with antibodies against antiapoptotic proteins of the Bcl-2 family and transcription factors NF-κB and signal transducer and activator of transcription 3 (STAT3). B, HCT-8 cells were untreated (−) or transfected with control siRNA (Ctrl), siUSP36#1 (#1), and siUSP36#2 (#2) for 72 h. Proteins were extracted and immunoblotted with antibodies against proapoptotic pore-forming proteins of the Bcl-2 family. C, HCT-8 cells were untreated (−) or transfected with control siRNA (Ctrl), siUSP36#1 (#1), and siUSP36#2 (#2) for 72 h. Proteins were extracted and immunoblotted with antibodies against proapoptotic BH3-only proteins of the Bcl-2 family. D, HCT-8 cells were untreated (−) or transfected with control siRNA (Ctrl), siUSP36#1 (#1), and siUSP36#2 (#2) for 72 h. Proteins were extracted and immunoblotted with antibodies from IAP family proteins. Bcl-2, B-cell leukemia 2; Bcl-xL, Bcl-extra-large; Bid, Bcl-2 homology 3–interacting domain death agonist; IAP, inhibitor of apoptosis protein; Mcl-1, myeloid cell leukemia sequence 1; USP36, ubiquitin-specific protease 36.